The emergence of CAR T-cell therapies has ignited a revolution in the field of cancer treatments. While existing products show outstanding curative capability, they are hampered by significant clinical and commercial challenges, many of which stem from their manufacturing process. Maciej Nakoniecznik discusses how a combination of biological and technological advances in the field may allow CAR T cells to reach their full therapeutic potential.

Chimeric antigen receptor  therapies target cancerous cells by utilising genetically modified T lymphocytes. This approach combines the specificity of a high-affinity, antibody-derived recognition domain with the cytolytic capabilities of T cells. Contrary to their natural mechanism of action, which involves the presentation of the antigen by the major histocompatibility complex and the activation of the T-cell receptor , CAR T cells can recognise and destroy target cells directly.

First-generation CAR constructs comprised three distinct elements: the antigen-binding domain, the transmembrane domain connected to it by the hinge, and the intracellular CD3ζ signalling domain. The following CAR generations contain additional co-stimulatory domains that enhance their clinical efficacy. A range of co-stimulatory domains have been evaluated for use in CAR T cells and their effect on the cells varies from an increase in potency and cytolytic activity to improved.

The procedure encompasses T-cell source collection and processing followed by CAR-T cell preparation; the latter involves T-cell selection and/or activation, genetic modification with a CAR cDNA followed by large-scale expansion, and end-of-process formulation. Chimeric antigen receptor T cells are T cells that have been genetically engineered to produce an artificial T-cell receptor for use in immunotherapy. Chimeric antigen receptors are receptor proteins that have been engineered to give T cells the new ability to target a specific protein.

Your immune system works by keeping track of all the substances normally found in your body. Any new substance the immune system doesn't recognize raises an alarm, causing the immune system to attack it. Chimeric antigen receptor  T-cell therapy is a promising new way to get immune cells called T cells (a type of white blood cell) to fight cancer by changing them in the lab so they can find and destroy cancer cells. CAR T-cell therapies are sometimes talked about as a type of gene or cell therapy, or immune effect cell therapy. The immune system recognizes foreign substances in the body by finding proteins called antigens on the surface of those cells. Immune cells called T cells have their own proteins called receptors that attach to foreign antigens and help trigger other parts of the immune system to destroy the foreign substance.

Media Contact
David Paul
Managing Editor
Journal of Infectious Diseases and Diagnosis